Viagra Label Change Delay Shows Need For Safety Reform – Sen. Grassley
Executive Summary
FDA's response to reports of vision loss in Viagra patients is being cited by Senate Finance Committee Chairman Charles Grassley (R-Iowa) as another reason to reform the agency's drug safety system
You may also be interested in...
Erectile Dysfunction Class Labeling Excludes Causal Link To Vision Loss
FDA's class labeling for oral erectile dysfunction disorder drugs on the incidence of non-arteritic anterior ischemic optic neuropathy notes that it is unknown whether the drugs are connected to the adverse events
Erectile Dysfunction Class Labeling Excludes Causal Link To Vision Loss
FDA's class labeling for oral erectile dysfunction disorder drugs on the incidence of non-arteritic anterior ischemic optic neuropathy notes that it is unknown whether the drugs are connected to the adverse events
Viagra Label Will Add Language On Blindness Incidence “In Near Future”
Pfizer expects to update Viagra labeling "in the near future" to reflect data on the incidence of vision loss in patients receiving the erectile dysfunction therapy